Advanced search
Publication Cover
Current Medical Research and Opinion Volume 33, 2017 - Issue 12
Submit an article Journal homepage
755
Views
3
CrossRef citations to date
0
Altmetric
Diabetes

iGlarLixi, a titratable once-daily fixed-ratio combination of basal insulin and lixisenatide for intensifying type 2 diabetes management for patients inadequately controlled on basal insulin with or without oral agents

Neil SkolnikAbington Family Medicine, Jenkintown, PA, USA; ;Abington Jefferson Health, Jenkintown, PA, USA; Correspondence[email protected]
,
Renell S. DupreeAbington Jefferson Health, Jenkintown, PA, USA;
&
Eric L. JohnsonUniversity of North Dakota School of Medicine and Health Sciences, Grand Forks, ND, USA
Pages 2187-2194 | Received 17 Mar 2017, Accepted 10 Jul 2017, Published online: 04 Aug 2017

Citations (3)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Lawrence Blonde, John E. Anderson, Pavan Chava & Jared A. Dendy. (2019) Rationale for a titratable fixed-ratio co-formulation of a basal insulin analog and a glucagon-like peptide 1 receptor agonist in patients with type 2 diabetes. Current Medical Research and Opinion 35:5, pages 793-804.
Read now

Articles from other publishers (2)

Domenico Tricò & Anna Solini. (2021) Glucagon-Like Peptide-1 Receptor Agonists—Use in Clinical Practice. Advances in Chronic Kidney Disease 28:4, pages 328-336.
Crossref
Francesco Giorgino, Irene Caruso & Raffaele Napoli. (2020) Titratable fixed-ratio combination of insulin glargine plus lixisenatide: A simplified approach to glycemic control in type 2 diabetes mellitus. Diabetes Research and Clinical Practice 170, pages 108478.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.